Clinical trials: COVID-19 Convalescent Plasma Treatment
COVID-19
Convalescent Plasma Therapy - Zurich Protocol
This is an open-label, single-center, phase I study to assess the safety and efficacy of convalescent plasma therapy (CPT) obtained from donors who were tested positive for SARS-CoV-2 and fully recovered from the infection and…
- Trial name
- CPT-ZHP (NCT04869072)
- Testing
- Convalescent plasma
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
COVID
Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2
Trial design. Randomized, double-blind, placebo-controlled trial in a catchment population of 2,020,860 age-appropriate subjects in the state of Buenos Aires and 235,000 in the city of Buenos Aires. Institutions.
- Trial name
- NCT04479163
- Testing
- Convalescent Plasma
- Where
- 11 sites in Argentina
- Volunteers
- 165 people
- Sponsor
- Fundacion Infant
COVID-19
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
This is a phase II randomized study of convalescent plasma for the treatment of non-immune individuals with COVID-19 infection at high risk of complications.
- Trial name
- NCT04456413
- Testing
- Convalescent Plasma, Best Supportive Care
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Hackensack Meridian Health
COVID-19
Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19
Background: The Coronavirus disease 2019 (COVID-19) pandemic is a major public health issue. Researchers want to collect plasma from people who have recovered from COVID-19, and use this plasma to treat people who are sick with…
- Trial name
- NCT04360278
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Convalescence, Corona Virus Infection
Convalescent Plasma Therapy in Patients With COVID-19
Scientists and medical workers all around the world were running out of time to manage COVID-19. Several studies have been done to understand the disease and ultimately to find possible treatment.
- Conditions
- Convalescence, Corona Virus Infection, Plaque
- Trial name
- NCT04407208
- Testing
- Convalescent plasma
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Biofarma
COVID, Corona Virus Infection
Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia
CCAP is an investigator-initiated multicentre, randomized, double blinded, placebo-controlled trial, which aims to assess the safety and efficacy of treatment with convalescent plasma for patients with moderate-severe COVID-19.
- Conditions
- COVID, Corona Virus Infection, Viral Pneumonia
- Trial name
- CCAP (NCT04345289)
- Testing
- Convalescent anti-SARS-CoV-2 plasma
- Where
- 12 sites in Denmark
- Volunteers
- 147 people
- Sponsor
- Thomas Benfield
COVID-19, Coronavirus
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting.
- Conditions
- COVID-19, Coronavirus, SARS-CoV-2
- Trial name
- PassItOn (NCT04362176)
- Testing
- pathogen reduced SARS-CoV-2 convalescent plasma
- Where
- 26 sites in United States
- Volunteers
- 974 people
- Sponsor
- Vanderbilt University Medical Center
COVID
Use of Convalescent Plasma for COVID-19
The plan is to transfuse COVID-19 infected patients with convalescent plasma and observe whether this will result in a significant improvement in clinical outcome in comparison to historical experience.
- Trial name
- NCT04408040
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northside Hospital, Inc.
Covid19
Convalescent Plasma Treatment in COVID-19
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred initially in December 2019 in the city of Wuhan, Hubei province, China.
- Trial name
- COLLATE (NCT04476888)
- Testing
- Convalescent Plasma (CP), Drugs and supportive care
- Where
- Pakistan
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
COVID-19, SARS-CoV-2 Infection
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
A prospective, randomized, placebo-controlled, double-blinded, phase III clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe COVID-19
- Conditions
- COVID-19, SARS-CoV-2 Infection, Severe Acute Respiratory Syndrome Coronavirus 2
- Trial name
- NCT04516811
- Testing
- COVID-19 convalescent plasma (CCP) plus standard of care (SOC)
- Where
- 2 sites in South Africa
- Volunteers
- 102 people
- Sponsor
- South African National Blood Service
Covid19
Convalescent Plasma in the Treatment of Covid-19
This study investigates the possible adverse effects and effectiveness of convalescent plasma for patients infected with SARS-CoV-2.
- Trial name
- CP_COVID-19 (NCT04730401)
- Testing
- Convalescent plasma from COVID-19 donors
- Where
- Finland
- Volunteers
- 390 people
- Sponsor
- Helsinki University Central Hospital
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients
Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill COVID-19 patients. The aim of this study is to determine whether combining TPE with convalescent plasma (CVP) transfusion early during the…
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, Acute Respiratory Failure, Acute Respiratory Distress Syndrome
- Trial name
- NCT04973488
- Testing
- Therapeutic plasma exchange
- Where
- Romania
- Volunteers
- 38 people
- Sponsor
- Novacescu Alexandru
COVID-19
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
The purpose of the study is to determine if Convalescent anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Methylene Blue Treated (MBT) plasma plus Standard Medical Treatment (SMT) can reduce all-cause mortality…
- Trial name
- NCT04547127
- Testing
- Convalescent anti-SARS-CoV-2 MBT Plasma, Standard Medical Treatment
- Where
- 12 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Instituto Grifols, S.A.
Covid19
Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)
An effective, widely available, and safe treatment that can decrease the duration, severity and fatality of COVID-19 is urgently needed.
- Trial name
- CoV-Early (NCT04589949)
- Testing
- ConvP, FFP
- Where
- 11 sites in Netherlands
- Volunteers
- 420 people
- Sponsor
- Erasmus Medical Center
Covid-19
Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma
Open label two arms, non randomized Convalescent Plasma treatment to severe and critical pneumonia COVID-19 hospitlaized patients compared to a historical cohort with matched controls.
- Trial name
- NCT04432103
- Testing
- Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients, Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients
- Where
- Mexico
- Volunteers
- 6 people
- Sponsor
- Centro Medico ABC
COVID, Sars-CoV2
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19
The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.
- Conditions
- COVID, Sars-CoV2, Corona Virus Infection
- Trial name
- NCT04445207
- Testing
- Convalescent Plasma
- Where
- United States
- Sponsor
- Jonathan Gerber
COVID-19
Convalescent Plasma as a Possible Treatment for COVID-19
Patients who are ill with COVID-19 may benefit from receiving convalescent plasma infusions containing antibodies from donors who have recovered from the disease and are proven to no longer be infected.
- Trial name
- NCT04442191
- Testing
- Convalescent plasma
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Illinois Chicago
COVID-19
A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19
This is a randomized, prospective, multicenter, open label clinical trial of convalescent plasma compared to best supportive care for treatment of patients with severe COVID-19.
- Trial name
- CAPSID (NCT04433910)
- Testing
- Convalesscent Plasma
- Where
- 16 sites in Germany
- Volunteers
- 106 people
- Sponsor
- Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen
COVID, SARS-CoV 2
Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19
No specific therapeutic agents or vaccines for COVID-19 are available. Several therapies, are under investigation, but the antiviral efficacy of these drugs is not yet known.
- Trial name
- TSUNAMI (NCT04393727)
- Testing
- CONVALESCENT PLASMA
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
COVID19
Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection
This clinical trial proposal is based on the FDA protocol for emergency use of convalescent plasma for treatment of COVID-19 cases, and on the WHO guidelines for use of convalescent plasma in other infectious diseases.
- Trial name
- CP IN COVID19 (NCT04438694)
- Testing
- Convalescent Plasma, Standard of Care
- Where
- Egypt
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Cairo University